🚀 VC round data is live in beta, check it out!
Spineway Valuation Multiples
Discover revenue and EBITDA valuation multiples for Spineway and similar public comparables like ScandiDos, Bio-Gate, Lucyd, Neola Medical and more.
Spineway Overview
About Spineway
Spineway designs produce and markets implant lines and ancillary surgical equipment used for the treatment of severe disorders of the spinal column. The group offers spinal systems, cervical and lumbar cages, cervical plates, bone substitutes, and other such medical instruments.
Founded
2005
HQ
Employees
54
Website
Sectors
Financials (LTM)
EV
$4M
Spineway Financials
Spineway reported last 12-month revenue of $15M and negative EBITDA of ($1M).
In the same LTM period, Spineway generated ($1M) in EBITDA losses and had net loss of ($3M).
Revenue (LTM)
Spineway P&L
In the most recent fiscal year, Spineway reported revenue of $14M and EBITDA of ($2M).
Spineway expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $15M | XXX | $14M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $10M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 71% | XXX | XXX | XXX |
| EBITDA | ($1M) | XXX | ($2M) | XXX | XXX | XXX |
| EBITDA Margin | (8%) | XXX | (14%) | XXX | XXX | XXX |
| EBIT Margin | (18%) | XXX | (7%) | XXX | XXX | XXX |
| Net Profit | ($3M) | XXX | ($5M) | XXX | XXX | XXX |
| Net Margin | (19%) | XXX | (32%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Spineway Stock Performance
Spineway has current market cap of $6M, and enterprise value of $4M.
Market Cap Evolution
Spineway's stock price is $0.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4M | $6M | -0.7% | XXX | XXX | XXX | $-0.13 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSpineway Valuation Multiples
Spineway trades at 0.2x EV/Revenue multiple, and (3.1x) EV/EBITDA.
EV / Revenue (LTM)
Spineway Financial Valuation Multiples
As of April 20, 2026, Spineway has market cap of $6M and EV of $4M.
Equity research analysts estimate Spineway's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Spineway has a P/E ratio of (2.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6M | XXX | $6M | XXX | XXX | XXX |
| EV (current) | $4M | XXX | $4M | XXX | XXX | XXX |
| EV/Revenue | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBITDA | (3.1x) | XXX | (1.8x) | XXX | XXX | XXX |
| EV/EBIT | (1.3x) | XXX | (3.4x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 0.4x | XXX | XXX | XXX |
| P/E | (2.2x) | XXX | (1.4x) | XXX | XXX | XXX |
| EV/FCF | (0.6x) | XXX | (0.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Spineway Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Spineway Margins & Growth Rates
Spineway's revenue in the last 12 month grew by 7%.
Spineway's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Spineway's rule of 40 is 7% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Spineway's rule of X is 17% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Spineway Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | (8%) | XXX | (14%) | XXX | XXX | XXX |
| EBITDA Growth | (120%) | XXX | (14%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 7% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 17% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 78% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Spineway Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Spineway | XXX | XXX | XXX | XXX | XXX | XXX |
| ScandiDos | XXX | XXX | XXX | XXX | XXX | XXX |
| Bio-Gate | XXX | XXX | XXX | XXX | XXX | XXX |
| Lucyd | XXX | XXX | XXX | XXX | XXX | XXX |
| Neola Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Qlife Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Spineway M&A Activity
Spineway acquired XXX companies to date.
Last acquisition by Spineway was on XXXXXXXX, XXXXX. Spineway acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Spineway
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSpineway Investment Activity
Spineway invested in XXX companies to date.
Spineway made its latest investment on XXXXXXXX, XXXXX. Spineway invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Spineway
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Spineway
| When was Spineway founded? | Spineway was founded in 2005. |
| Where is Spineway headquartered? | Spineway is headquartered in France. |
| How many employees does Spineway have? | As of today, Spineway has over 54 employees. |
| Is Spineway publicly listed? | Yes, Spineway is a public company listed on Euronext Paris. |
| What is the stock symbol of Spineway? | Spineway trades under ALSPW ticker. |
| When did Spineway go public? | Spineway went public in 2013. |
| Who are competitors of Spineway? | Spineway main competitors are ScandiDos, Bio-Gate, Lucyd, Neola Medical. |
| What is the current market cap of Spineway? | Spineway's current market cap is $6M. |
| What is the current revenue of Spineway? | Spineway's last 12 months revenue is $15M. |
| What is the current revenue growth of Spineway? | Spineway revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Spineway? | Current revenue multiple of Spineway is 0.2x. |
| Is Spineway profitable? | No, Spineway is not profitable. |
| What is the current EBITDA of Spineway? | Spineway has negative EBITDA and is not profitable. |
| What is Spineway's EBITDA margin? | Spineway's last 12 months EBITDA margin is (8%). |
| What is the current EV/EBITDA multiple of Spineway? | Current EBITDA multiple of Spineway is (3.1x). |
| What is the current FCF of Spineway? | Spineway's last 12 months FCF is ($6M). |
| What is Spineway's FCF margin? | Spineway's last 12 months FCF margin is (37%). |
| What is the current EV/FCF multiple of Spineway? | Current FCF multiple of Spineway is (0.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.